Irritable bowel syndrome
Conditions
Interventions
Experimental group1:Oral compound probiotics for 1 month
Experimental group2:Oral compound probiotic metabolites
Control group1:Oral placebo for 1 month in the compound probiotic group
Experimental group3:Oral Bifidobacterium infantis BX-01 for 1 month
Experimental group4:Oral bifidobacterium infantis BX-01metabolites
Control group2:Oral placebo for Bifidobacterium infantis BX-01 group for 1 month
Sponsors
Inner Mongolia People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Gender is not limited, aged 18 to 70 years; 2. No abnormal results of intestinal examination (colonoscopy or barium meal angiography); 3. Symptoms have been present for at least 6 months before diagnosis, and the past 3 months meet the following diagnosis: (1) Abnormal defecation frequency (defecation > 3 times per day or < 3 times per week); (2) Mucus stool; (3) Abnormal feces (blocky, hard or watery stools); (4) Flatulence or abdominal distention; (5) Abnormal excretion of feces (labor, urgency, and incomplete defecation).
Exclusion criteria
Exclusion criteria: 1. History and family history of colon cancer, celiac disease and inflammatory bowel disease; 2. Subjects who have major mental illnesses, have difficulty controlling their actions, and cannot cooperate; 3. Those who are trying to conceive recently (including men and women), pregnant or breastfeeding women; 4. Those who are allergic to samples or ingredients; 5. Have taken antibiotics, probiotics and probiotics-related preparations within the past 2 weeks; 6. Those who have taken anti-anxiety, anti-depression and other psychotropic drugs in the past 1 month; 7. Those who need to take long-term medication to improve constipation or diarrhea; 8. Those who have been diagnosed with myocardial infarction, cerebral infarction, malignant tumor and other serious diseases that researchers think are not suitable for enrollment; 9. Subjects who are illiterate, unable to understand informed consent, and unable to sign the informed consent form by themselves.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms;Intestinal mucosal barrier function;Intestinal flora;Inflammatory factor;Metabonomics; | — |
Countries
China
Contacts
Public ContactGuo Ruifang
Inner Mongolia People's Hospital
Outcome results
None listed